Veru (NASDAQ:VERU) PT Raised to $3.00 at HC Wainwright

Veru (NASDAQ:VERU - Get Free Report) had its target price raised by equities researchers at HC Wainwright from $2.00 to $3.00 in a research note issued on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 82.93% from the company's current price.

VERU has been the subject of several other research reports. Oppenheimer reaffirmed an "outperform" rating and set a $5.00 price target (down previously from $7.00) on shares of Veru in a report on Monday, April 15th. Raymond James started coverage on Veru in a report on Thursday, March 28th. They set an "outperform" rating and a $3.00 target price for the company.

Veru Stock Up 0.6 %

Shares of NASDAQ VERU traded up $0.01 during trading hours on Monday, hitting $1.64. The company had a trading volume of 1,978,816 shares, compared to its average volume of 2,402,984. The stock has a market capitalization of $240.06 million, a P/E ratio of -2.19 and a beta of -0.47. Veru has a 1-year low of $0.36 and a 1-year high of $1.92. The firm's 50 day moving average is $0.96 and its 200-day moving average is $0.80.

Veru (NASDAQ:VERU - Get Free Report) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.09) EPS for the quarter. The company had revenue of $2.14 million during the quarter. Veru had a negative net margin of 405.04% and a negative return on equity of 257.92%. On average, sell-side analysts predict that Veru will post -0.26 earnings per share for the current year.

Institutional Investors Weigh In On Veru

A number of large investors have recently bought and sold shares of VERU. Choreo LLC acquired a new stake in shares of Veru during the 1st quarter worth approximately $64,000. 180 Wealth Advisors LLC acquired a new stake in shares of Veru in the 1st quarter valued at $120,000. ADAR1 Capital Management LLC acquired a new stake in shares of Veru in the 4th quarter valued at $360,000. Worth Venture Partners LLC bought a new position in shares of Veru in the 4th quarter valued at $616,000. Finally, AIGH Capital Management LLC acquired a new position in shares of Veru during the 4th quarter worth $2,476,000. 47.16% of the stock is currently owned by institutional investors and hedge funds.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.